Published in Neurology on October 12, 2010
Fragile x-associated tremor ataxia syndrome: the expanding clinical picture, pathophysiology, epidemiology, and update on treatment. Tremor Other Hyperkinet Mov (N Y) (2012) 0.86
Ages of Onset of Mood and Anxiety Disorders in Fragile X Premutation Carriers. Curr Psychiatry Rev (2013) 0.84
Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers. Brain Disord Ther (2014) 0.81
FXTAS is rare among Portuguese patients with movement disorders: FMR1 premutations may be associated with a wider spectrum of phenotypes. Behav Brain Funct (2011) 0.80
COGNITIVE DYSFUNCTION IN FMR1 PREMUTATION CARRIERS. Curr Psychiatry Rev (2013) 0.79
Fragile X premutation in women: recognizing the health challenges beyond primary ovarian insufficiency. J Assist Reprod Genet (2016) 0.75
X-inactivation in the clinical phenotype of fragile X premutation carrier sisters. Neurol Genet (2016) 0.75
Risk Factors for Cognitive Impairment in Fragile X-Associated Tremor/Ataxia Syndrome. J Geriatr Psychiatry Neurol (2016) 0.75
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain (2005) 4.33
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology (2010) 4.06
Connexin-26 mutations in sporadic and inherited sensorineural deafness. Lancet (1998) 3.93
Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology (2005) 2.86
Early diagnosis of brain death in patients treated with central nervous system depressant drugs. Transplantation (2000) 2.07
Hepatic myelopathy: a rare complication of portacaval shunt. Eur Neurol (1994) 1.86
Implications of the FMR1 gene in menopause: study of 147 Spanish women. Menopause (2001) 1.58
Neurospectroscopic alterations and globus pallidus hyperintensity as related magnetic resonance markers of reversible hepatic encephalopathy. Neurology (1996) 1.52
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol (2013) 1.52
[Molecular analysis of the IT15 gene in 79 Spanish families with Huntington's disease: diagnostic confirmation and presymptomatic diagnosis]. Med Clin (Barc) (1997) 1.44
Motor changes during sertraline treatment in depressed patients with Parkinson's disease*. Eur J Neurol (2008) 1.43
Neuropsychological alterations in patients with computed tomography-detected basal ganglia calcification. Arch Neurol (1996) 1.20
A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene (2001) 1.11
X-chromosome tiling path array detection of copy number variants in patients with chromosome X-linked mental retardation. BMC Genomics (2007) 1.11
Incidence of fragile X in 5,000 consecutive newborn males. Genet Test (2003) 1.09
A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol (1999) 1.05
Elastin mutation screening in a group of patients affected by vascular abnormalities. Pediatr Cardiol (2006) 1.02
Fragile X syndrome and the (CGG)n mutation: two families with discordant MZ twins. Am J Hum Genet (1994) 1.02
Transcranial magnetic stimulation for treating depression. Cochrane Database Syst Rev (2002) 1.00
Relationship between cerebral perfusion in frontal-limbic-basal ganglia circuits and neuropsychologic impairment in patients with subclinical hepatic encephalopathy. J Nucl Med (2000) 0.99
Obsessive-compulsive disorder associated with brain lesions: clinical phenomenology, cognitive function, and anatomic correlates. Neurology (1996) 0.97
Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression. Neuroscience (2008) 0.97
Association between BDNF Val66Met polymorphism and age at onset in Huntington disease. Neurology (2005) 0.95
MLPA as first screening method for the detection of microduplications and microdeletions in patients with X-linked mental retardation. Genet Med (2007) 0.92
Alien hand sign after a right parietal infarction. Cerebrovasc Dis (2000) 0.91
Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease. Am J Kidney Dis (1999) 0.91
Contiguous deletion of the NDP, MAOA, MAOB, and EFHC2 genes in a patient with Norrie disease, severe psychomotor retardation and myoclonic epilepsy. Am J Med Genet A (2007) 0.90
Prevalence of Y chromosome microdeletions in oligospermic and azoospermic candidates for intracytoplasmic sperm injection. Fertil Steril (1998) 0.90
Motion of the cerebellar tonsils in Chiari type I malformation studied by cine phase-contrast MRI. Neurology (1995) 0.89
Bipolar disorder in adult patients with Tourette's syndrome: a clinical study. Biol Psychiatry (1998) 0.89
[Weight gain after functional surgery for Parkinsons disease]. Neurologia (2002) 0.88
Increased prevalence of polycystic kidney disease type 2 among elderly polycystic patients. Am J Kidney Dis (2000) 0.88
Mutational analysis within the 3' region of the PKD1 gene. Kidney Int (1999) 0.87
Complete deletion of ornithine transcarbamylase gene confirmed by CGH array of X chromosome. J Inherit Metab Dis (2007) 0.87
Analysis of CGG variation through 642 meioses in Fragile X families. Mol Hum Reprod (2004) 0.86
Efficacy and safety of pallidal stimulation in primary dystonia: results of the Spanish multicentric study. J Neurol Neurosurg Psychiatry (2009) 0.85
Single-strand conformation polymorphism analysis in the FMR1 gene. Am J Med Genet (1999) 0.85
Botulinum toxin injection therapy for hemifacial spasm. Adv Neurol (1988) 0.85
Gaba and serotonin molecular neuroimaging in essential tremor: a clinical correlation study. Parkinsonism Relat Disord (2012) 0.85
CDKN2A mutations in melanoma families from Uruguay. Br J Dermatol (2009) 0.84
Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA. Neurology (2005) 0.82
Intranuclear inclusions, neuronal loss and CAG mosaicism in two patients with Machado-Joseph disease. J Neurol Sci (2002) 0.82
Reactivation of posttraumatic stress disorder after minor head injury. Depress Anxiety (1998) 0.81
SCA8 in the Spanish population including one homozygous patient. Clin Genet (2002) 0.81
Effects of alprazolam on the acoustic startle response in humans. Psychopharmacology (Berl) (1999) 0.81
Pilot study for the neonatal screening of fragile X syndrome. Prenat Diagn (2002) 0.81
Huntington's disease: confirmation of diagnosis and presymptomatic testing in Spanish families by genetic analysis. J Neurol Neurosurg Psychiatry (1996) 0.80
Maternal transmission in sporadic Huntington's disease. J Neurol Neurosurg Psychiatry (1997) 0.80
Genes responsible for nonspecific mental retardation. Mol Genet Metab (2001) 0.80
Effects of repetitive transcranial magnetic stimulation on memory subtypes: a controlled study. Neuropsychologia (2003) 0.80
Mutational spectrum of phenylalanine hydroxylase deficiency in the population resident in Catalonia: genotype-phenotype correlation. Hum Genet (1999) 0.80
Motor circuitry re-organization after pallidotomy in Parkinson disease: a neurophysiological study of the bereitschaftspotential, contingent negative variation, and N30. J Clin Neurophysiol (2002) 0.80
Dentatorubropallidoluysian atrophy in a spanish family: a clinical, radiological, pathological, and genetic study. J Neurol Neurosurg Psychiatry (1999) 0.79
Chemiluminescent detection of blotted PCR products (CB-PCR) of two CAG dynamic mutations (Huntington's disease and spinocerebellar ataxia type 1). J Med Genet (1994) 0.79
Frontal lobe activation during word generation studied by functional MRI. Acta Neurol Scand (1996) 0.79
Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology (1999) 0.79
Deletion of the OPHN1 gene detected by aCGH. J Intellect Disabil Res (2008) 0.79
Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances. J Neural Transm (Vienna) (2009) 0.79
MicroRNA expression profiling in blood from fragile X-associated tremor/ataxia syndrome patients. Genes Brain Behav (2013) 0.79
[Movement disorders and AIDS]. Neurologia (1996) 0.79
SPECT mapping of cerebral activity changes induced by repetitive transcranial magnetic stimulation in depressed patients. A pilot study. Psychiatry Res (2001) 0.79
Genetic studies in variegate porphyria in Spain. Identification of gene mutations and family study for carrier detection. J Eur Acad Dermatol Venereol (2006) 0.79
Prenatal diagnosis of fragile X syndrome: (CGG)n expansion and methylation of chorionic villus samples. Prenat Diagn (1995) 0.78
Fragile X syndrome prenatal diagnosis: parental attitudes and reproductive responses. Reprod Biomed Online (2010) 0.78
Immunohistochemical FMRP studies in a full mutated female fetus. Am J Med Genet A (2004) 0.78
Scopolamine prevents tolerance to the effects of caffeine on rotational behavior in 6-hydroxydopamine-denervated rats. Eur J Pharmacol (1999) 0.77
Biochemical phenotype and its relationship with genotype in hyperphenylalaninemia heterozygotes. Mol Genet Metab (1999) 0.77
Methylxanthines reverse the adipsic and aphagic syndrome induced by bilateral 6-hydroxydopamine lesions of the nigrostriatal pathway in rats. Pharmacol Biochem Behav (2000) 0.77
YAC and cosmid FISH mapping of an unbalanced chromosomal translocation causing partial trisomy 21 and Down syndrome. Hum Genet (1996) 0.77
Magnetic resonance imaging pallidal hypersignal in cirrhotic subjects. Hepatology (1996) 0.77
Should levodopa dose be reduced when switched to stalevo? Eur J Neurol (2008) 0.77
Impulse control disorders and dopaminergic treatments in Parkinson's disease. Rev Neurol (Paris) (2011) 0.77
Abnormalities of the acoustic startle reflex and reaction time in gilles de la tourette syndrome. Clin Neurophysiol (2000) 0.77
Meige syndrome: primary and secondary forms. Adv Neurol (1988) 0.77
[Postural tremor: clinical and neurophysiological study in a consecutive series of 300 patients]. Med Clin (Barc) (2001) 0.77
[Sustained attention in the preclinical phase of Alzheimer's disease]. Rev Neurol (2003) 0.77
Large de novo deletion in chromosome 12 affecting the PAH, IGF1, ASCL1, and TRA1 genes. J Mol Med (Berl) (2001) 0.77
Uses of pharmaco-EEG and pharmacokinetic-pharmacodynamic modeling in the clinical scenario. Methods Find Exp Clin Pharmacol (2002) 0.76
[Dementia with Lewy bodies and Alzheimer's disease: differential diagnosis by cardiac sympathetic innervation MIBG imaging]. Rev Esp Med Nucl (2006) 0.76
Induction of complete and incomplete chromosome aberrations by bleomycin in human lymphocytes. Mutat Res (2007) 0.76
Cryptic chromosomal rearrangement screening in 30 patients with mental retardation and dysmorphic features. Clin Genet (2004) 0.76
Poststroke bipolar affective disorder: clinical subtypes, concurrent movement disorders, and anatomical correlates. J Neuropsychiatry Clin Neurosci (1996) 0.76
[Phenomenon of complete inversion of the visual image in an episode of transient vertebrobasilar ischemia]. Med Clin (Barc) (1994) 0.75
Withdrawal of visual feedback in essential tremor. Parkinsonism Relat Disord (2011) 0.75
Hepatoerythropoietic porphyria due to a novel mutation in the uroporphyrinogen decarboxylase gene. Br J Dermatol (2011) 0.75
Subcortical environmental reduplication: SPECT findings in a patient with a right thalamocapsular haemorrhage. J Neurol Neurosurg Psychiatry (1993) 0.75
Repeated co-administration of caffeine and bromocriptine prevents tolerance to the effects of caffeine in the turning behavior animal model. Eur Neuropsychopharmacol (1999) 0.75
Isolated lingual myoclonus associated with an Arnold-Chiari malformation. J Neurol Neurosurg Psychiatry (1994) 0.75
[Treatment of dystonic blepharospasm and hemifacial spasm with botulinum toxin: preliminary studies]. Med Clin (Barc) (1987) 0.75
Dopaminergic mechanisms in cranial dystonia. Adv Neurol (1988) 0.75
Evaluation of doctor/patient satisfaction with the use of the Parkinson's Disease Dementia-Short-Screen (PDD-SS): a screening test for dementia in Parkinson's disease (DIFFUSION study). Neurologia (2011) 0.75
[Pramipexole and Parkinson's disease, an update]. Rev Neurol (2008) 0.75
Short-lasting episodes of prosopagnosia in Parkinson's disease. Parkinsonism Relat Disord (2012) 0.75